Roche disclosed that giredestrant missed the primary progression‑free survival endpoint in the PersevERA Phase 3 first‑line trial for ER‑positive, HER2‑negative metastatic breast cancer. The failure undermines the drug’s potential positioning as a front‑line oral SERD and raises questions about optimal treatment niches for the class. The miss follows a turbulent period for oral SERDs and comes after giredestrant showed activity in other settings. Investors and competitors will recalibrate expectations: Roche may now re‑examine combination partners, line‑of‑therapy positioning, or biomarker‑defined subgroups. The result affects peers developing oral SERDs and could influence ongoing trials and regulatory strategies. Clinical note: oral selective estrogen receptor degraders (SERDs) have been pursued to overcome resistance to existing endocrine therapies; giredestrant’s setback highlights the challenge of translating biomarker signals into broad first‑line wins.